Skip to main content
Calman Prussin, MD, Allergy & Immunology, North Bethesda, MD

CalmanPhilipPrussinMD

Allergy & Immunology North Bethesda, MD

Chief Scientific Officer, Areteia Therapeutics

Dr. Prussin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Prussin's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1988 - 1994
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1984 - 1987
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 1984

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1991 - 2025
  • CA State Medical License
    CA State Medical License 1985 - 2024
  • MA State Medical License
    MA State Medical License 2003 - 2003
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial  
    Salman Siddiqui, BM, FRCP, PhD,a Sally E. Wenzel, MD,b Michael E. Bozik, MD,c Donald G. Archibald, MPhil,c Steven I. Dworetzky, PhD,c James L. Mather, BS,c Randall Kil..., Journal of Allergy and Clinical Immunology, 11/2023

Press Mentions

  • Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)
    Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022
  • Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
    Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
  • Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
    Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil SocietyJuly 9th, 2019
  • Join now to see all

Grant Support

  • Highly Differentiated Il5+ TH2 Cells In Food Allergy And Eosinophilic GI DiseaseNational Institute Of Allergy And Infectious Diseases2010–2011
  • Functional And Epigenetic Analysis Of TH2 HeterogeneityNational Institute Of Allergy And Infectious Diseases2010–2011
  • T Cell Pathogenesis Of Food AllergyNational Institute Of Allergy And Infectious Diseases2009
  • Developmental Immunotherapeutics Of Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2009
  • Memory T Cell Responses To Food AllergyNational Institute Of Allergy And Infectious Diseases2008
  • Developmental Immunotherapeutics Of Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2008
  • Induction And Inhibition Of Ige-Mediated Hypersensitivity To VaccinesNational Institute Of Allergy And Infectious Diseases2007
  • Developmental Immunotherapeutics For Allergic Diseases And AsthmaNational Institute Of Allergy And Infectious Diseases2007
  • Developmental Immunotherapeutics For Allergic Diseases ANational Institute Of Allergy And Infectious Diseases2002–2006
  • Cytokine Profiles In Asthma And Allergic DiseasesNational Institute Of Allergy And Infectious Diseases2002–2006
  • Developmental Immunotherapeutics-Allergic Disease/AsthmaNational Institute Of Allergy And Infectious Diseases2005
  • Immunotherapeutics For Allergic Diseases And AsthmaNational Institute Of Allergy And Infectious Diseases2003